TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03130959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT03671876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention plus therapy
Description: Task oriented exercise plan to improve mobility for stroke patients
Study: NCT04275258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan
Description: PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks.
Study: NCT03015298

Intervention type: DEVICE
Intervention: PET/MRI
Description: The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.

Intervention type: DEVICE
Intervention: PET/CT
Description: At the next day of PET/MRI examination,A PET/CT examination will be performed.
Study: NCT02817061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilux
Description: The Omnilux LED array sources can be changed to emit different wavelength.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Omnilux
Description: The Omnilux LED array sources can be changed to emit different wavelength.
Study: NCT02858635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and neuropsychological assessment, Blood and saliva samples
Description: Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
Study: NCT00198263

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medpulser Electroporation with Bleomycin
Description: The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
Study: NCT02196298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: 16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
Study: NCT02416453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
Study: NCT04145700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine given IV
Study: NCT03925129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency TENS treatment
Description: Treatment with high frequency for minimum of 1 hour after misoprostol administration

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS treatment
Description: Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
Study: NCT04145700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given IV
Study: NCT01802177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVB excimer light
Study: NCT04215445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: Tab.empagliflozin 25mg once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: Tab.empagliflozin 25mg once daily for 28 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-A
Description: Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-A
Description: Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
Study: NCT01011868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 placebo
Description: BI 10773 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 low dose
Description: BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 high dose
Description: BI 10773 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 10773 placebo
Description: BI 10773 placebo
Study: NCT00719329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 4.0%
Description: Solution (4.0%, 7.1% CHX-D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 4.0%
Description: Solution (4.0%, 7.1% CHX-D)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dry Cord Care
Description: Educational messages regarding clean cord care
Study: NCT04606498

Intervention type: OTHER
Intervention: Observational
Description: Observational study only - no intervention

Intervention type: OTHER
Intervention: Observational
Description: Observational study only - no intervention

Intervention type: OTHER
Intervention: Observational
Description: Observational study only - no intervention
Study: NCT00936572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Probiotics (La1, BB536)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotics (La1, BB536)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Maltodoxtrin
Study: NCT04332159

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Closed nasal fracture reduction
Description: Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed nasal fracture reduction
Description: Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo
Study: NCT01867320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
Study: NCT00570336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
Study: NCT01957423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein
Description: Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
Study: NCT00652704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate
Description: Capsules, 100 mg, fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monodox
Description: Capsules, 100 mg, fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: Capsules, 100 mg, fasting
Study: NCT03209193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane use as main anesthetic drug during the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane use as main anesthetic drug during the surgery
Study: NCT02541422

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl Cysteine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03944213

Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS)
Description: 20 sessions of iTBS
Study: NCT03735082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 250mg,qd,d1-14,14day/cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=4,d1,14day/cycle;
Study: NCT01967004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morph
Description: Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
Study: NCT03335319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodized Exercise Training Regime
Description: MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or \> 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Periodized Exercise Training Regime
Description: To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
Study: NCT03824717

Intervention type: DRUG
Group type: OTHER
Intervention: Dose of ropivacaine
Description: Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
Study: NCT02820870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Statin Decision Support Intervention
Description: The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline.
Study: NCT02829047

Intervention type: DEVICE
Group type: OTHER
Intervention: Vibrating Capsule
Description: Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
Study: NCT03545932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program hydrogymnastics
Description: 4 months of practice hydrogymnastics
Study: NCT02487537

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: custom-made soft drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: custom-made soft drink
Study: NCT04061278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy
Description: 4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy
Description: 3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
Study: NCT01152996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study: NCT01042821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial rectal wall advancement flap
Description: The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucosal advancement flap
Description: Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
Study: NCT03668665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ready Medical Post Treatment
Description: Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionell Treatment
Description: Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
Study: NCT00827515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH797804
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
Study: NCT01247350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03169907

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mid trimesteric fetal ultrasonography
Description: Venous and arterial Doppler indices:~1. Middle cerebral artery (MCA) peak systolic velocity (PSV):~2. Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~3. Ductus venosus (DV) Doppler:~Cardiac functions:~1. Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~2. Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~3. Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)
Study: NCT02895685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dyad training
Description: Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
Study: NCT01266824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride Ophthalmic Solution
Description: 1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
Study: NCT00576862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
Study: NCT00653367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve section
Description: Intercostal nerve is divided during surgery
Study: NCT03363867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
Study: NCT02921945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT800
Description: recombinant human coagulation factor VIII
Study: NCT02477878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501
Description: Biological: T cells transduced with CaspaCIDe suicide gene
Study: NCT01535027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide 20 ug/day, sc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide and raloxifene
Description: teriparatide 20 ug/day sc. raloxifene 60mg oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide and alendronate
Description: teriparatide 20 ug/day sc. alendronate 70mg oral weekly
Study: NCT02477878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid administered to treat GVHD
Study: NCT04263987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moses laser enucleation of prostate
Description: Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moses laser enucleation of prostate
Description: Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time